new semaglutide pill Novo Nordisk wins EU approval for Wegovy weight-loss Oral GLP-1 Wegovy chases approval

Background Oral semaglutide is a novel glucagon-like peptide-1 (GLP-1) analog that has been associated with improvements in glycated hemoglobin (HbA1c) and body weight versus sodium-glucose cotransporter-2 inhibitor empagliflozin and injectable GLP-1 receptor agonist dulaglutide in the PIONEER 2 clinical trial and in a recent network meta-analysis (NMA), respectively

GLP-1 medications like Ozempic show a 60% reduction in heavy drinking days

Interestingly, though products like Ozempic and Mounjaro are indicated for T2D like SGLT2s, the distribution of claims by payer channel differs between the classes

Reta GHKCU MOTSC TESA

These natural alternatives are cheaper, yet still effective for weight loss and blood sugar management without the hefty price tag and side effects of Ozempic.

Compounded Semaglutide GLP-1 vs